Аллогенная трансплантация гемопоэтических стволовых клеток при острых лейкозах: обзор литературы
Аннотация
Современные протоколы химиотерапии обеспечивают излечение до 90% детей с острым лимфобластным лейкозом (ОЛЛ). Тем не менее, существует риск развития рецидива заболевания после программного лечения. Трансплантация гемопоэтических стволовых клеток (ТГСК) является одним из основных существующих методов лечения рецидивов ОЛЛ. Показания к ТГСК при ОЛЛ продолжают пересматриваться вплоть до настоящего времени, так как совершенствуются протоколы лечения и выделяются новые подтипы заболевания, определяющие прогноз.
Литература
Литература/References:
1. Schultz K. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031 / Schultz K., Devidas M., Bowman W., Aledo A., Slayton W., Sather H. // Leukemia. – 2014. – №28(4). – P.964.
2. Schrappe M. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia / Schrappe M., Hunger S.P., Pui C.H., Saha V., Gaynon P.S., Baruchel A. // N Engl J Med. – 2012. – №366(15). – P.1371.
3. Pui C.H. Treating childhood acute lymphoblastic leukemia without cranial irradiation / Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C. // N Engl J Med. – 2009. –№360(26) – P.2730.
4. ALL IC-BFM 2009. A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia.
5. Dreyer Z.E. Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children’s Oncology Group / Dreyer Z.E., Dinndorf P.A, Camitta B., Sather H., La M.K., Devidas M. // J Clin Oncol. – 2011. – №29(2). – P.214.
6. Mann G. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study / Mann G., Attarbaschi A., Schrappe M., De Lorenzo P., Peters C., Hann I. // Blood. – 2010. – №116(15). – P.2644.
7. Schultz K.R. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study / Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M. // J Clin Oncol Off J Am Soc Clin Oncol. – 2009. – №27(31). – P.5175.
8. Pulsipher M.A. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL / Pulsipher M.A., Wayne A.S., Schultz K.R. // Bone Marrow Transplant. – 2014. – №49(10). – P.1259.
9. Saarinen-Pihkala U.M. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data / Saarinen-Pihkala U.M., Heilmann C., Winiarski J., Glomstein A., Abrahamsson J., Arvidson J. // J Clin Oncol Off J Am Soc Clin Oncol. – 2006. – №24(36). – Р.5750.
10. Davies S.M. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia / Davies S.M., Ramsay N.K., Klein J.P., Weisdorf D.J., Bolwell B. Cahn J.Y // J Clin Oncol Off J Am Soc Clin Oncol. – 2000. – №18(2). – Р.340.
11. Boztug H. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia / Boztug H., Zecca M., Sykora K.W., Veys P., Lankester A., Slatter M. // Ann Hematol. – 2015. – №94(2). – Р.297.
12. Pulsipher M.A. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial / Pulsipher M.A., Langholz B., Wall D.A., Schultz K.R., Bunin N., Carroll W.L. // Blood. – 2014. – №123(13). – Р.2017.
13. Carpenter P.A. Transplantation for AML in children / Carpenter P.A., Meshinchi S., Davies S.M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2012. – №18(1 Suppl). – Р.33.
14. Alonzo T.A. Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group / Alonzo T.A., Ho P.A., Gerbing R.B., Gamis A.S., Raimondi S.C., Hirsch B.A. // Blood. – 2010. – №116(21). – Р.761.
15. Slavin S. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases / Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G. // Blood. – 1998. – № 91(3). –Р.756.
16. Abdul Wahid S.F. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis / Abdul Wahid S.F., Ismail N.A., Mohd-Idris M.R., Jamaluddin F.W., Tumian N., Sze-Wei E.Y. // Stem Cells Dev. – 2014. – №23(21). – P.2535.
17. Luger S.M. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS / Luger S.M., Ringdén O., Zhang M.J., Pérez W.S., Bishop M.R., Bornhauser M. // Bone Marrow Transplant. – 2012. – №47(2). – P.203.
18. Ishida H. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents / Ishida H., Adachi S., Hasegawa D., Okamoto Y., Goto H., Inagaki J. / Pediatr Blood Cancer // – 2015. – №62(5). – P.883.
19. Bitan M. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens / Bitan M., He W., Zhang M.J., Abdel-Azim H., Ayas M.F., Bielorai B. // Blood. – 2014. – №123(10) – P.1615.
20. Baron F. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation / Baron F., Labopin M., Niederwieser D., Vigouroux S., Cornelissen J.J., Malm C. // Leukemia. – 2012. – №26(12). – P.2462.
21. Weisdorf D. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning / Weisdorf D., Zhang M.J., Arora M., Horowitz M.M., Rizzo J.D., Eapen M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2012. – №18(11). – P.1727.
22. Shaw P.J. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors / Shaw P.J., Kan F., Woo Ahn K., Spellman S.R. Aljurf M., Ayas M. // Blood. – 2010. – №116(19). – P.4007.
23. Schwartz E. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors / Schwartz E., Lapidot T., Gozes D., Singer T.S., Reisner Y. // J Immunol Baltim Md 1950. – 1987. – №138(2). – P.460.
24. Cobbold S.P. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance / Cobbold S.P., Martin G., Qin S., Waldmann H. // Nature – 1986. – №323(6084). – P.164.
25. Terenzi A. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa / Terenzi A., Lubin I., Lapidot T., Salomon O., Faktorowich Y., Rabi I. // Transplantation. – 1990. – №50(4). – P.717.
26. Aversa F. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse / Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S. // J Clin Oncol Off J Am Soc Clin Oncol. – 2005. – №23(15). – P.3447.
27. Aversa F. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum / Aversa F., Tabilio A., Terenzi A., Velardi A., Falzetti F., Giannoni C // Blood. – 1994. – №84(11). – P.3948.
28. Schumm M. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device / Schumm M., Lang P., Taylor G., Kuçi S., Klingebiel T., Bühring H.J. // J Hematother. – 1999 – №8(2). – P.209.
29. Klingebiel T. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group / Klingebiel T., Cornish J., Labopin M., Locatelli F., Darbyshire P., Handgretinger R. // Blood. – 2010 – №115(17) – P.3437.
30. Ciceri F. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation / Ciceri F., Labopin M., Aversa F., Rowe J.M., Bunjes D., Lewalle P // Blood. – 2008. – №112(9). – P.3574.
31. Barfield R.C. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation / Barfield R.C., Otto M., Houston J., Holladay M., Geiger T., Martin J. // Cytotherapy. – 2004. – №6(1). – P.1.
32. Oevermann L. New strategies for haploidentical transplantation / Oevermann L. Handgretinger R. // Pediatr Res. – 2012. – №71. – P.418.
33. Hale G.A. Haploidentical Stem Cell Transplantation with CD3 Depleted Mobilized Peripheral Blood Stem Cell Grafts for Children with Hematologic Malignancies / Hale G.A., Kasow K.A., Gan K., Horwitz E., Woodard J.P., Yusuf U. // Blood. – 2005. – №106(11). – P.2910.
34. Hale G.A. Mismatched Family Member Donor Transplantation for Patients with Refractory Hematologic Malignancies: Long-Term Followup of a Prospective Clinical Trial / Hale G.A., Kasow K.A., Madden R., Yusuf U., Horwitz E., Barfield R. // Blood. – 2006. №108(11). – P.3137.
35. Handgretinger R. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation / Handgretinger R., Chen X., Pfeiffer M., Mueller I., Feuchtinger T., Hale G.A. // Ann N Y Acad Sci. – 2007. – №1106. – P.279.
36. Federmann B. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study Federmann B., Bornhauser M., Meisner C., Kordelas L., Beelen D.W., Stuhler G. // Haematologica. – 2012. – №97(10). – P.1523.
37. Bader P. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells / Bader P., Soerensen J., Jarisch A., Ponstingl E., Krenn T., Faber J. // Best Pract Res Clin Haematol. – 2011. – №24(3). –P.331.
38. Dufort G. Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay / Dufort G., Pisano S., Incoronato A., Castiglioni M., Carracedo M., Pagés C. // Bone Marrow Transplant. –2012. – №47(5). – P.663.
39. Palma J. Haploidentical stem cell transplantation for children with high-risk leukemia / Palma J., Salas L., Carrión F., Sotomayor C., Catalán P., Paris C. // Pediatr Blood Cancer. – 2012. – №59(5). – P.895.
40. Gonzalez-Vicent M. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients / Gonzalez-Vicent M., Perez A., Abad L., Sevilla J., Ramirez M., Diaz M.A. // J Pediatr Hematol Oncol. – 2010. – №32(3). – P.85.
41. Oevermann L. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation / Oevermann L., Lang P., Feuchtinger T., Schumm M., Teltschik H.M., Schlegel P. // Ann N Y Acad Sci. – 2012. – №1266. – P.161.
42. Locatelli F. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation / Locatelli F., Vinti L., Palumbo G., Rossi F., Bertaina A., Mastronuzzi A. // Best Pract Res Clin Haematol. –2011. – №24(3). – P.339.
43. Azevedo R.I. Long-term immune reconstitution of naive and memory t cell pools after haploidentical hematopoietic stem cell transplantation / Azevedo R.I., Soares M.V.D., Albuquerque A.S., Tendeiro R., Soares R.S., Martins M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2013. – №19(5). – P.703.
44. Bonneville M. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity / Bonneville M., O’Brien R.L., Born W.K. // Nat Rev Immunol. – 2010. – №10(7). – P.467.
45. Godder K.T. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation / Godder K.T., Henslee-Downey P.J., Mehta J., Park B.S., Chiang K.Y., Abhyankar S. // Bone Marrow Transplant. – 2007. – №39(12). – P.751.
46. Chiplunkar S. gammadelta T cells in cancer immunotherapy: current status and future prospects / Chiplunkar S., Dhar S., Wesch D., Kabelitz D. // Immunotherapy. –2009. – №1(4). – P.663.
47. Lang P. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients / Lang P., Feuchtinger T., Teltschik H.M., Schwinger W., Schlegel P., Pfeiffer M. // Bone Marrow Transplant. – 2015. – №50. – P.6.
48. Kaynar L. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients / Kaynar L., Demir K., Turak E.E., Öztürk Ç.P., Zararsız G., Gönen Z.B. // Hematol Amst Neth. – 2017. – №22(3). – P.136.
49. Dodero A. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery / Dodero A., Carniti C., Raganato A., Vendramin A., Farina L., Spina F. // Blood. – 2009. – №113(19). – P.4771.
50. Amrolia P.J. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation / Amrolia P.J., Muccioli-Casadei G., Huls H., Adams S., Durett A., Gee A. // Blood. 2006 – №108(6). – P.1797.
51. Mielke S. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique / Mielke S., Nunes R., Rezvani K., Fellowes V.S., Venne A., Solomon S.R. // Blood. – 2008. – №111(8). – P.4392.
52. Feuchtinger T. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation / Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M. // Blood. – 2010. – №116(20). – P.4360.
53. Feuchtinger T. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation / Feuchtinger T., Matthes-Martin S., Richard C., Lion T., Fuhrer M., Hamprecht K. // Br J Haematol. – 2006. – №134(1). – P.64.
54. Lugthart G. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy / Lugthart G., Albon S.J., Ricciardelli I., Kester M.G.D., Meij P., Lankester A.C. // J Immunother Hagerstown Md –1997. – 2012. – №35(1). –P.42.
55. Di Ianni M. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation / Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E. // Blood. – 2011. – №117(14). – P.3921.
56. Passweg J.R. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation / Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kühne T. // Leukemia. – 2004. – №18(11). – P.1835.
57. Rubnitz J.E. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia / Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T. // J Clin Oncol Off J Am Soc Clin Oncol. – 2010. – №28(6). – P.955.
58. Rizzieri D.A. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation / Rizzieri D.A., Storms R., Chen D.F., Long G., Yang Y., Nikcevich D.A. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2010. –№16(8). – P.1107.
1. Schultz K. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031 / Schultz K., Devidas M., Bowman W., Aledo A., Slayton W., Sather H. // Leukemia. – 2014. – №28(4). – P.964.
2. Schrappe M. Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia / Schrappe M., Hunger S.P., Pui C.H., Saha V., Gaynon P.S., Baruchel A. // N Engl J Med. – 2012. – №366(15). – P.1371.
3. Pui C.H. Treating childhood acute lymphoblastic leukemia without cranial irradiation / Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C. // N Engl J Med. – 2009. –№360(26) – P.2730.
4. ALL IC-BFM 2009. A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia.
5. Dreyer Z.E. Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children’s Oncology Group / Dreyer Z.E., Dinndorf P.A, Camitta B., Sather H., La M.K., Devidas M. // J Clin Oncol. – 2011. – №29(2). – P.214.
6. Mann G. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study / Mann G., Attarbaschi A., Schrappe M., De Lorenzo P., Peters C., Hann I. // Blood. – 2010. – №116(15). – P.2644.
7. Schultz K.R. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study / Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M. // J Clin Oncol Off J Am Soc Clin Oncol. – 2009. – №27(31). – P.5175.
8. Pulsipher M.A. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL / Pulsipher M.A., Wayne A.S., Schultz K.R. // Bone Marrow Transplant. – 2014. – №49(10). – P.1259.
9. Saarinen-Pihkala U.M. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data / Saarinen-Pihkala U.M., Heilmann C., Winiarski J., Glomstein A., Abrahamsson J., Arvidson J. // J Clin Oncol Off J Am Soc Clin Oncol. – 2006. – №24(36). – Р.5750.
10. Davies S.M. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia / Davies S.M., Ramsay N.K., Klein J.P., Weisdorf D.J., Bolwell B. Cahn J.Y // J Clin Oncol Off J Am Soc Clin Oncol. – 2000. – №18(2). – Р.340.
11. Boztug H. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia / Boztug H., Zecca M., Sykora K.W., Veys P., Lankester A., Slatter M. // Ann Hematol. – 2015. – №94(2). – Р.297.
12. Pulsipher M.A. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial / Pulsipher M.A., Langholz B., Wall D.A., Schultz K.R., Bunin N., Carroll W.L. // Blood. – 2014. – №123(13). – Р.2017.
13. Carpenter P.A. Transplantation for AML in children / Carpenter P.A., Meshinchi S., Davies S.M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2012. – №18(1 Suppl). – Р.33.
14. Alonzo T.A. Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group / Alonzo T.A., Ho P.A., Gerbing R.B., Gamis A.S., Raimondi S.C., Hirsch B.A. // Blood. – 2010. – №116(21). – Р.761.
15. Slavin S. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases / Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G. // Blood. – 1998. – № 91(3). –Р.756.
16. Abdul Wahid S.F. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis / Abdul Wahid S.F., Ismail N.A., Mohd-Idris M.R., Jamaluddin F.W., Tumian N., Sze-Wei E.Y. // Stem Cells Dev. – 2014. – №23(21). – P.2535.
17. Luger S.M. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS / Luger S.M., Ringdén O., Zhang M.J., Pérez W.S., Bishop M.R., Bornhauser M. // Bone Marrow Transplant. – 2012. – №47(2). – P.203.
18. Ishida H. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents / Ishida H., Adachi S., Hasegawa D., Okamoto Y., Goto H., Inagaki J. / Pediatr Blood Cancer // – 2015. – №62(5). – P.883.
19. Bitan M. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens / Bitan M., He W., Zhang M.J., Abdel-Azim H., Ayas M.F., Bielorai B. // Blood. – 2014. – №123(10) – P.1615.
20. Baron F. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation / Baron F., Labopin M., Niederwieser D., Vigouroux S., Cornelissen J.J., Malm C. // Leukemia. – 2012. – №26(12). – P.2462.
21. Weisdorf D. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning / Weisdorf D., Zhang M.J., Arora M., Horowitz M.M., Rizzo J.D., Eapen M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2012. – №18(11). – P.1727.
22. Shaw P.J. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors / Shaw P.J., Kan F., Woo Ahn K., Spellman S.R. Aljurf M., Ayas M. // Blood. – 2010. – №116(19). – P.4007.
23. Schwartz E. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors / Schwartz E., Lapidot T., Gozes D., Singer T.S., Reisner Y. // J Immunol Baltim Md 1950. – 1987. – №138(2). – P.460.
24. Cobbold S.P. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance / Cobbold S.P., Martin G., Qin S., Waldmann H. // Nature – 1986. – №323(6084). – P.164.
25. Terenzi A. Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa / Terenzi A., Lubin I., Lapidot T., Salomon O., Faktorowich Y., Rabi I. // Transplantation. – 1990. – №50(4). – P.717.
26. Aversa F. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse / Aversa F., Terenzi A., Tabilio A., Falzetti F., Carotti A., Ballanti S. // J Clin Oncol Off J Am Soc Clin Oncol. – 2005. – №23(15). – P.3447.
27. Aversa F. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum / Aversa F., Tabilio A., Terenzi A., Velardi A., Falzetti F., Giannoni C // Blood. – 1994. – №84(11). – P.3948.
28. Schumm M. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device / Schumm M., Lang P., Taylor G., Kuçi S., Klingebiel T., Bühring H.J. // J Hematother. – 1999 – №8(2). – P.209.
29. Klingebiel T. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group / Klingebiel T., Cornish J., Labopin M., Locatelli F., Darbyshire P., Handgretinger R. // Blood. – 2010 – №115(17) – P.3437.
30. Ciceri F. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation / Ciceri F., Labopin M., Aversa F., Rowe J.M., Bunjes D., Lewalle P // Blood. – 2008. – №112(9). – P.3574.
31. Barfield R.C. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation / Barfield R.C., Otto M., Houston J., Holladay M., Geiger T., Martin J. // Cytotherapy. – 2004. – №6(1). – P.1.
32. Oevermann L. New strategies for haploidentical transplantation / Oevermann L. Handgretinger R. // Pediatr Res. – 2012. – №71. – P.418.
33. Hale G.A. Haploidentical Stem Cell Transplantation with CD3 Depleted Mobilized Peripheral Blood Stem Cell Grafts for Children with Hematologic Malignancies / Hale G.A., Kasow K.A., Gan K., Horwitz E., Woodard J.P., Yusuf U. // Blood. – 2005. – №106(11). – P.2910.
34. Hale G.A. Mismatched Family Member Donor Transplantation for Patients with Refractory Hematologic Malignancies: Long-Term Followup of a Prospective Clinical Trial / Hale G.A., Kasow K.A., Madden R., Yusuf U., Horwitz E., Barfield R. // Blood. – 2006. №108(11). – P.3137.
35. Handgretinger R. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation / Handgretinger R., Chen X., Pfeiffer M., Mueller I., Feuchtinger T., Hale G.A. // Ann N Y Acad Sci. – 2007. – №1106. – P.279.
36. Federmann B. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study Federmann B., Bornhauser M., Meisner C., Kordelas L., Beelen D.W., Stuhler G. // Haematologica. – 2012. – №97(10). – P.1523.
37. Bader P. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells / Bader P., Soerensen J., Jarisch A., Ponstingl E., Krenn T., Faber J. // Best Pract Res Clin Haematol. – 2011. – №24(3). –P.331.
38. Dufort G. Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay / Dufort G., Pisano S., Incoronato A., Castiglioni M., Carracedo M., Pagés C. // Bone Marrow Transplant. –2012. – №47(5). – P.663.
39. Palma J. Haploidentical stem cell transplantation for children with high-risk leukemia / Palma J., Salas L., Carrión F., Sotomayor C., Catalán P., Paris C. // Pediatr Blood Cancer. – 2012. – №59(5). – P.895.
40. Gonzalez-Vicent M. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients / Gonzalez-Vicent M., Perez A., Abad L., Sevilla J., Ramirez M., Diaz M.A. // J Pediatr Hematol Oncol. – 2010. – №32(3). – P.85.
41. Oevermann L. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation / Oevermann L., Lang P., Feuchtinger T., Schumm M., Teltschik H.M., Schlegel P. // Ann N Y Acad Sci. – 2012. – №1266. – P.161.
42. Locatelli F. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation / Locatelli F., Vinti L., Palumbo G., Rossi F., Bertaina A., Mastronuzzi A. // Best Pract Res Clin Haematol. –2011. – №24(3). – P.339.
43. Azevedo R.I. Long-term immune reconstitution of naive and memory t cell pools after haploidentical hematopoietic stem cell transplantation / Azevedo R.I., Soares M.V.D., Albuquerque A.S., Tendeiro R., Soares R.S., Martins M. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2013. – №19(5). – P.703.
44. Bonneville M. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity / Bonneville M., O’Brien R.L., Born W.K. // Nat Rev Immunol. – 2010. – №10(7). – P.467.
45. Godder K.T. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation / Godder K.T., Henslee-Downey P.J., Mehta J., Park B.S., Chiang K.Y., Abhyankar S. // Bone Marrow Transplant. – 2007. – №39(12). – P.751.
46. Chiplunkar S. gammadelta T cells in cancer immunotherapy: current status and future prospects / Chiplunkar S., Dhar S., Wesch D., Kabelitz D. // Immunotherapy. –2009. – №1(4). – P.663.
47. Lang P. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients / Lang P., Feuchtinger T., Teltschik H.M., Schwinger W., Schlegel P., Pfeiffer M. // Bone Marrow Transplant. – 2015. – №50. – P.6.
48. Kaynar L. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients / Kaynar L., Demir K., Turak E.E., Öztürk Ç.P., Zararsız G., Gönen Z.B. // Hematol Amst Neth. – 2017. – №22(3). – P.136.
49. Dodero A. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery / Dodero A., Carniti C., Raganato A., Vendramin A., Farina L., Spina F. // Blood. – 2009. – №113(19). – P.4771.
50. Amrolia P.J. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation / Amrolia P.J., Muccioli-Casadei G., Huls H., Adams S., Durett A., Gee A. // Blood. 2006 – №108(6). – P.1797.
51. Mielke S. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique / Mielke S., Nunes R., Rezvani K., Fellowes V.S., Venne A., Solomon S.R. // Blood. – 2008. – №111(8). – P.4392.
52. Feuchtinger T. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation / Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M. // Blood. – 2010. – №116(20). – P.4360.
53. Feuchtinger T. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation / Feuchtinger T., Matthes-Martin S., Richard C., Lion T., Fuhrer M., Hamprecht K. // Br J Haematol. – 2006. – №134(1). – P.64.
54. Lugthart G. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy / Lugthart G., Albon S.J., Ricciardelli I., Kester M.G.D., Meij P., Lankester A.C. // J Immunother Hagerstown Md –1997. – 2012. – №35(1). –P.42.
55. Di Ianni M. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation / Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E. // Blood. – 2011. – №117(14). – P.3921.
56. Passweg J.R. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation / Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kühne T. // Leukemia. – 2004. – №18(11). – P.1835.
57. Rubnitz J.E. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia / Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T. // J Clin Oncol Off J Am Soc Clin Oncol. – 2010. – №28(6). – P.955.
58. Rizzieri D.A. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation / Rizzieri D.A., Storms R., Chen D.F., Long G., Yang Y., Nikcevich D.A. // Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. – 2010. –№16(8). – P.1107.
Опубликована
2023-12-25
Как цитировать
СУББОТИНА, Н. А. et al.
Аллогенная трансплантация гемопоэтических стволовых клеток при острых лейкозах: обзор литературы.
Новообразование, [S.l.], v. 15, n. 3, p. 15-22, дек. 2023.
ISSN 2521-117X.
Доступно на: <http://donetsk-onco.com/neoplasm/index.php/Neoplasm/article/view/495>. Дата доступа: 21 апр. 2025
Раздел
Обзоры литературы
